Generate Biomedicines, the Somerville-based AI drug design company, has struck a partnership with Copenhagen's Zealand Pharma worth up to nearly $1.2 billion to develop protein-based treatments for obesity and other metabolic diseases. Generate will collect $30 million upfront, with the potential for up to $35 million more tied to early preclinical milestones, and the rest contingent on hitting development, regulatory, and commercial targets down the line.
How the Partnership Splits the Work
Under the arrangement, Generate will lead research through the selection of lead drug candidates, while Zealand Pharma takes over clinical development, regulatory submissions, and eventual commercialization, according to Reuters. The deal establishes two initial metabolic disease programs, with an option for Zealand to add a third built on Generate's generative AI platform, according to GlobeNewswire. Ropes & Gray LLP served as legal counsel to Generate on the transaction, while Cooley LLP advised Zealand Pharma, per StreetInsider's reporting.
News of the agreement sent Generate Biomedicines shares up about 5% in extended trading, Reuters reported. The company went public on Nasdaq in February, a milestone Hoodline covered in its piece on the Somerville biotech's IPO gambit, when it sold 25 million shares at $16 apiece, raising roughly $400 million at an initial valuation near $2.2 billion.
A Deal Rooted in Somerville and Cambridge
The partnership lands just months after Zealand Pharma expanded its own footprint in the Boston area, opening a research facility in Cambridge aimed at hiring 50 to 100 people in computational biology, lab automation, and chemistry. That hub sits just a few miles from Generate's Somerville headquarters, reinforcing how tightly the two companies' operations are now intertwined in the region's life-sciences cluster.
Generate Biomedicines was founded in 2018 by Cambridge-based Flagship Pioneering, the same firm that previously incubated mRNA developer Moderna using a comparable platform-building approach, according to Forbes. Generate has already pushed its lead computationally designed antibody, GB-0895, for severe asthma into Phase 3 trials, making it one of the first AI-focused biotechs to reach that stage. The company has also inked prior generative AI collaborations with Novartis, worth up to $1 billion with $65 million upfront in September 2024, and with Amgen, worth up to $1.9 billion back in January 2022, per BioSpace.
Zealand's Bet on Life Beyond GLP-1s
Zealand Pharma, founded in 1998 and headquartered in Copenhagen, has advanced more than 10 internally discovered drug candidates into clinical trials over its history, yielding two commercialized products and three late-stage assets, according to Investing.com. The company has been building out a non-GLP-1 obesity portfolio anchored by petrelintide, its once-weekly long-acting amylin analog. Zealand reported Phase 2b ZUPREME-2 trial results showing up to 9.2% body weight loss at 28 weeks in adults with overweight or obesity and type 2 diabetes, BioSpace reported.
Petrelintide is also the centerpiece of a separate, massive bet: in March 2025, Zealand entered a global co-development agreement worth up to $5.3 billion with Roche, advancing the drug into a 7,000-patient Phase 3 trial program set to begin later this year, as Hoodline detailed in its earlier coverage of Zealand's Boston research hub. That track record of high-value partnerships underscores why Zealand is now leaning on Generate's computational platform to chase additional mechanisms beyond amylin.
The push comes as financial analysts project the global market for anti-obesity and GLP-1 therapies could expand to between $114 billion and $190 billion by 2035, driven by demand for novel mechanisms, oral formulations, and expanded healthcare coverage, according to Morgan Stanley. As competition intensifies in that market, biotechs are increasingly turning to AI tools to engineer multispecific protein drugs aimed at improving tolerability and hitting multiple targets at once, moving beyond the first generation of GLP-1 injectables.
